These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 22819849)
1. Proteasome deubiquitinases as novel targets for cancer therapy. D'Arcy P; Linder S Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849 [TBL] [Abstract][Full Text] [Related]
2. Targeting the ubiquitin proteasome system in haematological malignancies. Crawford LJ; Irvine AE Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816 [TBL] [Abstract][Full Text] [Related]
3. Targeting the ubiquitin+proteasome system in solid tumors. Driscoll JJ; Woodle ES Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552 [TBL] [Abstract][Full Text] [Related]
4. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors? Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292 [TBL] [Abstract][Full Text] [Related]
6. Molecular pathways: translational potential of deubiquitinases as drug targets. D'Arcy P; Linder S Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788 [TBL] [Abstract][Full Text] [Related]
7. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells. Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676 [TBL] [Abstract][Full Text] [Related]
8. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524 [TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154 [TBL] [Abstract][Full Text] [Related]
10. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347 [TBL] [Abstract][Full Text] [Related]
14. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase. Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502 [TBL] [Abstract][Full Text] [Related]
15. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. Zhao C; Chen X; Yang C; Zang D; Lan X; Liao S; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; Dou QP; Wang X; Liu J Oncotarget; 2017 Feb; 8(8):13942-13956. PubMed ID: 28086217 [TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of deubiquitinating enzyme inhibitors. Colland F Biochem Soc Trans; 2010 Feb; 38(Pt 1):137-43. PubMed ID: 20074048 [TBL] [Abstract][Full Text] [Related]
17. Proteasome-associated deubiquitinases and cancer. Mofers A; Pellegrini P; Linder S; D'Arcy P Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486 [TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Park J; Cho J; Song EJ Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832 [TBL] [Abstract][Full Text] [Related]
19. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910 [TBL] [Abstract][Full Text] [Related]
20. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15. Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]